IOncology Archives - Page 156 of 164

ESMO China Voice | Professor Xiaohua Wu’s Team Presents Two LBA Studies at ESMO, Adding Chinese Solutions to Gynecological Cancer Treatment

By Peter W. PENG 2023.11.16

On October 20, the 2023 European Society for Medical Oncology (ESMO) Congress officially opened in Madrid, Spain. As one of the most influential global oncology conferences, top experts from around the world gathered to discuss and share the latest international research findings and cancer treatment technologies. Professor Xiaohua Wu's team from Fudan University Affiliated Cancer Hospital presented two significant studies at the ESMO 2023 Late-breaking Abstract (LBA) session, providing important references for clinical practice. "Oncology Frontier" had the privilege of inviting Professor Xiaohua Wu to share the research findings on-site.

ESMO 2023: EGFR-MET Dual-Specific Antibody Combination Emerges as a New Option for EGFR-Mutant Advanced NSCLC

By Peter W. PENG 2023.11.16

According to the reports from Phase III MARIPOSA and MARIPOSA-2 trials presented at the 2023 ESMO Presidential Symposium, Amivantamab combination therapy demonstrated clinically significant improvements in both first-line and second-line treatments compared to standard therapy (Abstract Numbers LBA14 and LBA15).

ESMO in Five Minutes | Prof. Haitao Zhao : Highlights of Advances in the Treatment of Cholangiocarcinoma

By Peter W. PENG 2023.11.16

Fibroblast Growth Factor Receptor inhibitors (FGFRi) have been shown to play a role in the treatment of cholangiocarcinoma (CCA) with FGFR alterations after chemotherapy. However, disease progression occurs after 6-8 months. Secondary multiclonal mutations in the FGFR2 kinase domain represent a notable acquired resistance mechanism. Tinengotinib is identified as a novel FGFRi with high efficacy against various FGFR2 kinase domain mutations and has shown promising clinical results in CCA patients previously treated with FGFRi. This study presents summary data from three trials.

Dr. Liang Han: Phase III MATTERHORN Study Shows Significant Improvement in pCR for Neoadjuvant Treatment of Gastric Cancer with Pembrolizumab

By Peter W. PENG 2023.11.13

This 2023 ESMO Annual Meeting, in the field of gastric cancer, the global Phase III MATTERHORN study of the anti-PD-L1 antibody pembrolizumab in combination with the FLOT regimen for neoadjuvant treatment in resectable gastric and gastroesophageal junction adenocarcinoma (GC/GEJC) was presented as a Late-breaking Abstract (LBA) with mid-term analysis results (Abstract No.: LBA73). The mid-term analysis showed a clinically and statistically significant improvement in the pathological complete response (pCR) rate, making MATTERHORN the first neoadjuvant Phase III immunotherapy regimen in gastric cancer to show positive results. "Tumor Outlook" invited Professor Liang Han from Tianjin Medical University Cancer Hospital to provide an in-depth interpretation of the study.

ESMO 2023 | Dr. Silvia Stacchiotti: Advancements and Challenges in Treating Metastatic Sarcoma

By Peter W. PENG 2023.11.13

Metastatic sarcoma presents a formidable challenge in the realm of cancer treatment. The sheer diversity of sarcoma subtypes and the necessity of tailoring treatments to each specific histology makes the quest for effective therapies all the more complex. In this article, we delve deeper into the current landscape of advancements and challenges in the treatment of metastatic sarcoma, guided by the insights of Professor Stacchiotti.

ESMO 2023 | Dr. Andrea Necchi: Advancements in Intravesical Delivery Systems for the Treatment of Bladder Cancer

By Peter W. PENG 2023.11.13

Bladder cancer presents a complex challenge that demands innovative approaches to treatment. In recent years, significant progress has been made in the development of intravesical delivery systems for targeted therapy in bladder cancer patients. This article aims to provide a comprehensive overview of the latest advancements in intravesical delivery systems, with a particular focus on the TAR200 and TAR21210 systems. The application of intravesical delivery systems holds profound clinical significance in the treatment of bladder cancer. These systems provide a continuous and controlled exposure of the tumor to therapeutic agents, significantly enhancing the likelihood of successful treatment outcomes. Moreover, intravesical delivery systems offer a valuable alternative to radical cystectomy, a surgical procedure that certain patients may decline or be medically unfit for. The ultimate goal is to preserve the bladder while achieving a cure and preventing disease progression

ESMO 2023 | Dr. Ryan J. Sullivan: When does targeted therapy outperform immunotherapy in patients with advanced melanoma?

By Peter W. PENG 2023.11.13

The landscape of advanced melanoma treatment has witnessed a remarkable transformation with the introduction of targeted therapies and immunotherapies. While immunotherapy has shown great promise in various cancer types, there exist specific scenarios where targeted therapy can outshine immunotherapy. In this article, we delve into the situations where targeted therapy may be the preferred choice for advanced melanoma patients, while also examining the comparative efficacy and potential side effects of these treatment approaches.

ESMO 2023 | Dr. Henrik Grönberg: Outcome Adaptive Design and Biomarker-Based Treatment Selection

By Peter W. PENG 2023.11.06

Prostate cancer remains a significant global health concern, predominantly affecting men. In recent groundbreaking research led by Dr. Henrik Grönberg, a novel approach known as outcome adaptive design was implemented to revolutionize the assessment of different drugs simultaneously. This innovative study design incorporated the dynamic adjustment of randomization probabilities based on individual patient outcomes, enabling the selection of the most suitable treatment for each person. Furthermore, the study harnessed the power of biomarkers, particularly circulating tumor DNA, to guide treatment selection, ultimately aiming to enhance patient outcomes and overall quality of life.

ESMO 2023 | Dr. Kjetil Boye: Emerging Therapeutic Strategies and Promising Drugs May Benefit Sarcoma Patients

By Peter W. PENG 2023.11.06

The field of sarcoma treatment is currently undergoing a remarkable transformation with the development of cutting-edge therapeutic strategies and promising drugs. This article aims to provide an in-depth overview of these emerging treatment options and highlight key findings from recent research, shedding light on the potential breakthroughs in sarcoma management.

ESMO 2023 | Dr. Oliver Sartor: Lu-PSMA therapy could benefit mCRPC patients

By Peter W. PENG 2023.11.06

Prostate cancer remains a significant health concern, especially in its metastatic castration-resistant form, which poses a formidable challenge for both patients and healthcare providers. Despite ongoing advancements in treatment options, the battle against this deadly disease continues. However, recent research has illuminated a ray of hope through the use of PSMA Lutetium therapy. In this article, we delve into the insights presented by Dr. Oliver Sartor at ESMO 2023 regarding the safety, efficacy, and potential benefits of PSMA Lutetium therapy in the treatment of metastatic castration-resistant prostate cancer.